Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.80 |
| ▸ | ATM | Q13315 | 1/20 | 0.80 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14731737 | 0.90 | GAA (0.80) | GAAATMTMEM97SIGMAR1KCNH2 | |
| SCHEMBL14731749 | 0.89 | GAA (0.81) | GAAATMTMEM97SIGMAR1ADRB2 | |
| SCHEMBL14731883 | 0.89 | GAA (1.00) | GAAATMTMEM97SIGMAR1ADRB2 | |
| SCHEMBL14731797 | 0.88 | GAA (0.77) | GAAATMTMEM97SIGMAR1KCNH2 | |
| SCHEMBL14731800 | 0.88 | GAA (0.72) | GAAATMTMEM97SIGMAR1KCNH2 | |
| SCHEMBL14731802 | 0.88 | GAA (0.80) | GAAATMTMEM97SIGMAR1KCNH2 | |
| SCHEMBL16774021 | 0.88 | GAA (0.80) | GAAATMTMEM97SIGMAR1ADRB2 | |
| SCHEMBL14731835 | 0.87 | GAA (0.68) | GAAATMTMEM97SIGMAR1KCNH2 | |
| SCHEMBL14731709 | 0.85 | GAA (0.72) | GAAATMTMEM97SIGMAR1KCNH2 | |
| SCHEMBL14731729 | 0.85 | TMEM97 (0.81) | GAAATMTMEM97SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105968022-A | Inhibitors of cognitive decline | 考格尼申治疗股份有限公司 | 2016-09-28 | — | — | CN | claimed |
| US-9365491-B2 | Inhibitors of cognitive decline | COGNITION THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | claimed |
| EP-2416795-B1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS INC (US) | 2015-06-03 | — | — | EP | claimed |
| US-20140371324-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-18 | — | — | US | claimed |
| US-8765816-B2 | Inhibitors of cognitive decline | COGNITION THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | claimed |
| US-20120095105-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | claimed |
| EP-2416795-A1 | Inhibitors of cognitive decline | Cognition Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| WO-2010118055-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170197977-A9 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160355458-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355458-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355458-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. | 2016-12-08 | — | — | US | disclosed |
| CN-105968022-A | Inhibitors of cognitive decline | 考格尼申治疗股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2013029060-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20120095105-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095105-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2416795-A1 | Inhibitors of cognitive decline | Cognition Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118055-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118055-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | GAA 1564/4885ATM 4274/4885TMEM97 1/4885 |
| US-20120095105-A1 | INHIBITORS OF COGNITIVE DECLINE | PSEN2, ACHE, MAPT | GAA 452/4885ATM 1315/4885TMEM97 3465/4885 |
| US-20140371324-A1 | INHIBITORS OF COGNITIVE DECLINE | PSEN2, ACHE, MAPT | GAA 452/4885ATM 1315/4885TMEM97 3465/4885 |
| US-20160355458-A1 | INHIBITORS OF COGNITIVE DECLINE | PSEN2, ACHE, MAPT | GAA 452/4885ATM 1315/4885TMEM97 3465/4885 |
| US-20170197977-A9 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, CHRNB2 | GAA 1453/4885ATM 4389/4885TMEM97 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.